Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference
May 26, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights
May 17, 2021 16:01 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
Cue Biopharma to Host Business Update Call and Webcast
May 10, 2021 10:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
May 10, 2021 08:00 ET
|
Cue Biopharma, Inc.
And Provides Interim Clinical Data Update Partial response data demonstrates activity of CUE-101 as monotherapy in patient with human papilloma virus positive recurrent/metastatic head and neck...
Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference
May 06, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
March 16, 2021 16:01 ET
|
Cue Biopharma, Inc.
Evaluated initial observations in CUE-101 Phase 1 monotherapy dose escalation clinical trial for treatment of human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma...
Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference
March 15, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Host Business Update Call and Webcast
March 09, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference
March 01, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
February 25, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...